Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec PDF Print E-mail
Monday, 02 November 2009 18:35
Gleevec® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate Gleevec® for the treatment of non-malignant diseases, including chronic graft-versus-host disease, lung fibrosis, pulmonary hypertension and systemic sclerosis. As of November 1, 2009 the website lists 119 on-going treatment trials with Gleevec®, including six in systemic sclerosis.

Preliminary results from several small open-label clinical trials of Gleevec® in systemic sclerosis were presented at the Annual Meeting of the American College of Rheumatology in Philadelphia (October 18, 2009). While some of the studies report softening of the skin and stabilization of lung abnormalities, the results represent only interim analysis, and studies are still on-going. Side effects (not necessarily related to the study medication) including swelling and fluid retention, nausea, muscle aching and elevated muscle enzymes, and fatigue were common, and in some cases led to discontinuing the medication.

The efficacy and safety of Gleevec® for the treatment of systemic sclerosis are still not well understood, and the interim results from uncontrolled clinical trials are too preliminary for reliable conclusions. Although preclinical research indicates that Gleevec® might be effective for fibrosis, such results cannot be directly extrapolated into the clinical setting. Some people might respond to Gleevec® while others do not. The safety of Gleevec® in systemic sclerosis needs careful evaluation, as does the right dose and duration of treatment. At this time Gleevec® for the treatment for systemic sclerosis should be limited to research studies.

Article courtesy the Scleroderma Foundation.
More articles :

» A Perspective on Juvenile Systemic Sclerosis

Juvenile systemic sclerosis is one of the most serious rheumatologic diseases diagnosed in children and adolescents, according to Dr. Ivan Foeldvari. This complex disorder is characterized by fibrosis of the skin, subcutaneous tissues, and internal...

» What You Should Know About The AntiNuclear Antibody Or ANA Test

How is it used?The ANA test is ordered to help screen for autoimmune disorders and is most often used as one of the tests to diagnose (SLE). Depending on the patient's symptoms and the suspected diagnosis, ANA may be ordered along with one or more...

» New Biomarker Predicts Poor Outcomes in Scleroderma

A novel biomarker may aid in establishing the prognosis of Systemic Sclerosis (Scleroderma), and particularly in predicting the most common lethal complications, an international group of researchers reported.Patients with Systemic Sclerosis who had...

» Study Suggests Link Between Scleroderma, Cancer in Certain Patients

Patients with a certain type of may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.These findings could lead researchers closer to discovering...

» New Research Finds Pattern For Detecting 'False-positive' ANA Results

The presence of antinuclear antibodies (ANA) indicates the possibility of and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive"...

» Targeting Systemic Sclerosis: From Bioinformatics to Clinical Research

Systemic sclerosis (SSc), also known as Scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Dartmouth's Geisel School of Medicine and Northwestern University's Feinberg School of...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code